Bank of New York Mellon Corp trimmed its stake in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 0.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 254,763 shares of the biotechnology company’s stock after selling 1,683 shares during the quarter. Bank of New York Mellon Corp owned about 1.31% of Enanta Pharmaceuticals worth $18,045,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its position in shares of Enanta Pharmaceuticals by 64.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 634 shares of the biotechnology company’s stock worth $45,000 after buying an additional 249 shares during the last quarter. Bank of Montreal Can increased its stake in shares of Enanta Pharmaceuticals by 33.0% in the fourth quarter. Bank of Montreal Can now owns 870 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 216 shares during the period. People s United Financial Inc. acquired a new stake in shares of Enanta Pharmaceuticals in the third quarter valued at about $212,000. Pacer Advisors Inc. acquired a new stake in shares of Enanta Pharmaceuticals in the third quarter valued at about $230,000. Finally, Victory Capital Management Inc. acquired a new stake in shares of Enanta Pharmaceuticals in the third quarter valued at about $245,000. Hedge funds and other institutional investors own 86.61% of the company’s stock.
NASDAQ ENTA opened at $91.50 on Tuesday. Enanta Pharmaceuticals Inc has a one year low of $64.08 and a one year high of $127.77. The company has a market cap of $1.82 billion, a P/E ratio of 26.29 and a beta of 1.38.
Several brokerages have recently weighed in on ENTA. Zacks Investment Research cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. BidaskClub raised Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 24th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $104.00.
In related news, Director George Golumbeski sold 9,280 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $103.65, for a total transaction of $961,872.00. Following the completion of the sale, the director now directly owns 9,280 shares of the company’s stock, valued at $961,872. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Yat Sun Or sold 27,684 shares of the stock in a transaction that occurred on Monday, February 11th. The shares were sold at an average price of $89.39, for a total value of $2,474,672.76. Following the sale, the vice president now directly owns 320,169 shares of the company’s stock, valued at $28,619,906.91. The disclosure for this sale can be found here. Insiders sold 59,514 shares of company stock worth $5,632,849 in the last 90 days. Corporate insiders own 11.35% of the company’s stock.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
Read More: Golden Cross
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.